IgGenix Presents Groundbreaking Research Using its SEQ SIFTER™ Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual Meeting

Research Outcomes Include a Novel IgG4 Monoclonal Antibody-based Therapeutic Approach for Addressing Peanut Allergy SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ — IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks